Mona Ashiya Sells 10,011 Shares of Disc Medicine, Inc. (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON) Director Mona Ashiya sold 10,011 shares of the business’s stock in a transaction that occurred on Friday, March 21st. The stock was sold at an average price of $54.00, for a total transaction of $540,594.00. Following the completion of the sale, the director now owns 187,297 shares of the company’s stock, valued at approximately $10,114,038. The trade was a 5.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Mona Ashiya also recently made the following trade(s):

• On Wednesday, March 19th, Mona Ashiya sold 39,656 shares of Disc Medicine stock. The shares were sold at an average price of $54.02, for a total transaction of $2,142,217.12.
• On Wednesday, March 12th, Mona Ashiya sold 83,182 shares of Disc Medicine stock. The stock was sold at an average price of $54.45, for a total value of $4,529,259.90.
• On Monday, March 10th, Mona Ashiya sold 202,146 shares of Disc Medicine stock. The shares were sold at an average price of $54.29, for a total value of $10,974,506.34.

Disc Medicine Stock Down 1.9 %

Shares of IRON stock traded down $0.99 on Friday, hitting $52.24. The company had a trading volume of 1,082,703 shares, compared to its average volume of 360,836. Disc Medicine, Inc. has a twelve month low of $25.60 and a twelve month high of $68.73. The firm has a market cap of $1.81 billion, a P/E ratio of -13.13 and a beta of 0.73. The company has a 50-day moving average price of $55.26 and a 200-day moving average price of $56.02.

Disc Medicine (NASDAQ:IRON) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.08. Equities research analysts expect that Disc Medicine, Inc. will post -4.07 EPS for the current year.

Institutional Trading of Disc Medicine

Several large investors have recently added to or reduced their stakes in IRON. GF Fund Management CO. LTD. acquired a new stake in Disc Medicine during the fourth quarter worth $40,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Disc Medicine by 399.2% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 93,103 shares of the company’s stock valued at $5,903,000 after acquiring an additional 74,454 shares in the last quarter. Woodline Partners LP increased its stake in Disc Medicine by 5.2% during the 4th quarter. Woodline Partners LP now owns 396,600 shares of the company’s stock worth $25,144,000 after buying an additional 19,538 shares during the period. ProShare Advisors LLC increased its position in shares of Disc Medicine by 26.5% during the fourth quarter. ProShare Advisors LLC now owns 6,966 shares of the company’s stock worth $442,000 after acquiring an additional 1,458 shares during the period. Finally, MPM Bioimpact LLC increased its holdings in Disc Medicine by 11.1% during the 4th quarter. MPM Bioimpact LLC now owns 346,401 shares of the company’s stock worth $21,962,000 after purchasing an additional 34,640 shares during the period. 83.70% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently commented on IRON. Morgan Stanley reissued an “overweight” rating and issued a $85.00 target price on shares of Disc Medicine in a research note on Friday, March 7th. Stifel Nicolaus lifted their target price on shares of Disc Medicine from $90.00 to $94.00 and gave the stock a “buy” rating in a research report on Friday, January 24th. Scotiabank upped their price target on shares of Disc Medicine from $73.00 to $75.00 and gave the company a “sector outperform” rating in a research report on Monday, March 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $118.00 target price on shares of Disc Medicine in a report on Tuesday, January 21st. Finally, Cantor Fitzgerald lifted their price target on shares of Disc Medicine from $99.00 to $132.00 and gave the company an “overweight” rating in a report on Tuesday. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $93.80.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.